Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567796 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 3,400
- Enrollment target
- 20
- Study locations
NCT05567796: Active Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
NCT05567796 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 3,400 participants, above the 816-participant average among 1,053 other Obesity trials with a reported enrollment target (317% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05567796, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
Primary Outcome
Measured in percentage (%)
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Cagrilintide
- DRUG Placebo cagrilintide
- DRUG Placebo semaglutide
Study Locations (20)
Florida
- Northeast Research Institute - Fleming Island
- South Broward Research LLC - Miramar
- Clinical Neuroscience Solution - Orlando
- Florida Inst For Clin Res - Orlando
- Clinical Trial Res Assoc,Inc - Plantation
Illinois
- Great Lakes Clinical Trials - Chicago
- Endeavor Health - Skokie
- Evanston Premier Hlthcr Res - Skokie
California
- Velocity Clin Res Los Angeles - Los Angeles
- Velocity Clin Res Wstlke - Los Angeles
Colorado
- Univ of Colorado at Denver - Aurora
- New West Physicians,Inc. - Golden
New York
- Velocity Clinical Research Binghamton - Binghamton
- Comprehensive Weight Ctrl Prog - New York
Alabama
- Univ of Alabama Birmingham - Birmingham
Georgia
- Hope Clin Res & Wellness - Conyers
Hawaii
- East West Med Res Inst - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,400 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2026-10-19 |
| Phase | Phase 3 |
What the registry record for NCT05567796 still lists
NCT05567796 is an interventional study that assigns participants to a tested intervention. Its 3,400 participants enrollment target places it among the larger protocols in the corpus, above the 816-participant average among 1,053 other Obesity trials with a reported enrollment target (317% higher).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.
NCT05567796 names 20 study sites across 11 states, led by Florida, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT05567796 about?
NCT05567796 is a clinical study titled "A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight". This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will loo...
What is the current status of trial NCT05567796?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 3,400 participants. The study started on 2022-11-01. Estimated completion is 2026-10-19.
What conditions does trial NCT05567796 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05567796?
The interventions under investigation include: Semaglutide (DRUG), Cagrilintide (DRUG), Placebo cagrilintide (DRUG), Placebo semaglutide (DRUG).
Who is sponsoring clinical trial NCT05567796?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05567796 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05567796's enrollment target sits among peer trials
3,400 31st of 1053 higher than 1,023 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI